These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19139107)

  • 1. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
    Ihle NT; Powis G
    Mol Cancer Ther; 2009 Jan; 8(1):1-9. PubMed ID: 19139107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K inhibitors for cancer therapy: what has been achieved so far?
    Wu P; Liu T; Hu Y
    Curr Med Chem; 2009; 16(8):916-30. PubMed ID: 19275602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should individual PI3 kinase isoforms be targeted in cancer?
    Jia S; Roberts TM; Zhao JJ
    Curr Opin Cell Biol; 2009 Apr; 21(2):199-208. PubMed ID: 19200708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
    Elmenier FM; Lasheen DS; Abouzid KAM
    Eur J Med Chem; 2019 Dec; 183():111718. PubMed ID: 31581005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
    Dienstmann R; Rodon J; Serra V; Tabernero J
    Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
    Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
    Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
    Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
    Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
    Singh P; Kumar V; Gupta SK; Kumari G; Verma M
    Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
    Akinleye A; Avvaru P; Furqan M; Song Y; Liu D
    J Hematol Oncol; 2013 Nov; 6(1):88. PubMed ID: 24261963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P3Kα: a driver of tumor metastasis?
    Zawel L
    Oncotarget; 2010 Sep; 1(5):315-316. PubMed ID: 21307397
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PI3K inhibitor].
    Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
    Doepfner KT; Boller D; De Laurentiis A; Guerreiro AS; Marinov M; Arcaro A
    Recent Pat DNA Gene Seq; 2007; 1(1):9-23. PubMed ID: 19075915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
    Iida M; Harari PM; Wheeler DL; Toulany M
    Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.
    Ciraolo E; Morello F; Hirsch E
    Curr Med Chem; 2011; 18(18):2674-85. PubMed ID: 21649577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of class I, II and III PI 3-kinases in platelet production and activation and their implication in thrombosis.
    Valet C; Severin S; Chicanne G; Laurent PA; Gaits-Iacovoni F; Gratacap MP; Payrastre B
    Adv Biol Regul; 2016 May; 61():33-41. PubMed ID: 26714793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From the bench to the bed side: PI3K pathway inhibitors in clinical development.
    Maira SM; Finan P; Garcia-Echeverria C
    Curr Top Microbiol Immunol; 2010; 347():209-39. PubMed ID: 20582534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.